Table 5 Summary of all the adverse events under fasted administration.

From: Pharmacokinetic evaluation of two oral Resveratrol formulations in a randomized, open-label, crossover study in healthy fasting subjects

Preferred terminology (PT)

T1 n (%)

T2 n (%)

Total n (%)

All TEAEs

10 (58.82)

7(41.18)

17 (100.00)

Proteinuria

0 (0.00)

2 (11.76)

2 (11.76)

Chest tightness

3 (17.65)

1 (5.88)

4 (23.53)

Nausea

4 (23.53)

0 (0.00)

4 (23.53)

Low blood pressure

0 (0.00)

1 (5.88)

1 (5.88)

Drowsiness

1 (5.88)

0 (0.00)

1 (5.88)

Dry throat

0 (0.00)

1 (5.88)

1 (5.88)

Foreign body sensation in the throat

0 (0.00)

1 (5.88)

1 (5.88)

Dizziness

1 (5.88)

0 (0.00)

1 (5.88)

Dry mouth

0 (0.00)

1 (5.88)

1 (5.88)

Abdominal pain

1 (5.88)

0 (0.00)

1 (5.88)

  1. TEAEs were defined as AEs that occurred after the start of drug administration. The percentage was calculated based on the total number of adverse event occurrences in this table.
  2. TEAE treatment-emergent adverse events.
Back to article page